Benefit/Risk Assessment for Breast Cancer Chemoprevention With Raloxifene or Tamoxifen for Women Age 50 Years or Older

PURPOSE: The Study of Tamoxifen and Raloxifene (STAR) demonstrated that raloxifene was as effective as tamoxifen in reducing the risk of invasive breast cancer (IBC) in postmenopausal women and had lower risks of thromboembolic events, endometrial cancer, and cataracts but had a nonstatistically sig...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Freedman, Andrew N., Yu, Binbing, Gail, Mitchell H., Costantino, Joseph P., Graubard, Barry I., Vogel, Victor G., Anderson, Garnet L., McCaskill-Stevens, Worta
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2011
Témata:
Original Reports
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3107748/
https://ncbi.nlm.nih.gov/pubmed/21537036
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.33.0258
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky